Intra-Cellular Therapies (ITCI) Tops Q4 Loss Expectations

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.67), $0.23 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $30.66 million versus the consensus estimate of $60 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
• CEMEX, S.A.B. de C.V. (CX) Tops Q1 EPS by 5c
• Airbus revenue rises, delivers 142 commercial aircraft in Q1